Defining a new era of oligonucleotides

Defining a new era of oligonucleotides

We are a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases.

Our chemistry platform enables the creation of highly specific, well characterized oligonucleotides designed to deliver superior efficacy and safety across multiple therapeutic modalities. Our pipeline is initially focused on neurological disorders and extends across several other therapeutic areas.

1 st

first to design and bring stereopure and
allele-specific medicines to clinic

3

clinical studies initiated in 2017

5

nucleic acid modalities being advanced with Wave stereopure chemistry

12+

discovery programs

 

Investor Relations

Recent News

Mar 29, 2021

Wave Life Sciences Provides Update on Phase 1b/2a PRECISION-HD Trials

mHTT results from PRECISION-HD trials do not support further development of WVE-120102 and WVE-120101 No observed change in wtHTT and NfL during trials Advancing Phase 1b/2a trial for WVE-003 (SNP3) program in HD; WVE-003 uses new PN backbone chemistry modifications, which demonstrate improved

Mar 19, 2021

Wave Life Sciences to Present at the Third Annual Stifel CNS Day

CAMBRIDGE, Mass. , March 19, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno , MD, MBA, President and Chief Executive

Events

Recent News

Mar 29, 2021

Wave Life Sciences Provides Update on Phase 1b/2a PRECISION-HD Trials

mHTT results from PRECISION-HD trials do not support further development of WVE-120102 and WVE-120101 No observed change in wtHTT and NfL during trials Advancing Phase 1b/2a trial for WVE-003 (SNP3) program in HD; WVE-003 uses new PN backbone chemistry modifications, which demonstrate improved

Mar 19, 2021

Wave Life Sciences to Present at the Third Annual Stifel CNS Day

CAMBRIDGE, Mass. , March 19, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno , MD, MBA, President and Chief Executive
Recent News and Events

Data Provided by Refinitiv. Minimum 15 minutes delayed.